Albertas Ulys
Overview
Explore the profile of Albertas Ulys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bogemann M, Shore N, Smith M, Tammela T, Ulys A, Vjaters E, et al.
Eur Urol
. 2022 Dec;
83(2):e60.
PMID: 36526492
No abstract available.
12.
Bogemann M, Shore N, Smith M, Tammela T, Ulys A, Vjaters E, et al.
Eur Urol
. 2022 Sep;
83(3):212-221.
PMID: 36089529
Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have a high risk of progression to metastatic disease, particularly if their prostate-specific antigen doubling time (PSADT) is ≤6 mo. However, patients...
13.
Makevicius J, Cekauskas A, Zelvys A, Ulys A, Jankevicius F, Miglinas M
Medicina (Kaunas)
. 2022 May;
58(5).
PMID: 35630084
Background and Objectives: Consequences of partial nephrectomy (PN), intraoperative hypotension (IOH) and postoperative neutrophil to lymphocyte ratio (NLR) may cause postoperative acute kidney injury (AKI) and in long-term-chronic kidney disease...
14.
Snipaitiene K, Bakavicius A, Lazutka J, Ulys A, Jankevicius F, Jarmalaite S
Prostate
. 2021 Dec;
82(4):475-482.
PMID: 34970742
Background: Despite novel agents have been introduced to treat castration resistant prostate cancer (CRPC) during the last decade, up to one-third of CRPC patients face primary resistance to new generation...
15.
Dabkeviciene D, Vincerzevskiene I, Urbonas V, Venius J, Dulskas A, Brasiuniene B, et al.
Healthcare (Basel)
. 2021 Nov;
9(11).
PMID: 34828568
The pandemic spread of the COVID-19 virus significantly affected daily life, but the highest pressure was piled on the health care system. Our aim was to evaluate an impact of...
16.
Kubiliute R, Zukauskaite K, Zalimas A, Ulys A, Sabaliauskaite R, Bakavicius A, et al.
J Cancer Res Clin Oncol
. 2021 Oct;
148(2):361-375.
PMID: 34689221
Objective: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney tumor characterized by the highest mortality rate of the genitourinary cancers, and, therefore, new diagnostic and/or...
17.
Kubiliute R, Zalimas A, Bakavicius A, Ulys A, Jankevicius F, Jarmalaite S
Onco Targets Ther
. 2021 Oct;
14:4979-4990.
PMID: 34675538
Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney tumors, accounting for the majority of deaths from genitourinary cancers. The currently used nomograms for predicting...
18.
Bosas P, Zaleskis G, Dabkeviciene D, Dobrovolskiene N, Mlynska A, Tikuisis R, et al.
J Clin Med
. 2021 Aug;
10(16).
PMID: 34442004
Background: Prostate cancer (PCa) is known to exhibit a wide spectrum of aggressiveness and relatively high immunogenicity. The aim of this study was to examine the effect of tumor excision...
19.
Smith M, Shore N, Tammela T, Ulys A, Vjaters E, Polyakov S, et al.
Eur J Cancer
. 2021 Jul;
154:138-146.
PMID: 34273811
Background: In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT significantly improved metastasis-free survival (MFS), overall survival (OS) and time to pain progression in patients...
20.
Daniunaite K, Bakavicius A, Zukauskaite K, Rauluseviciute I, Lazutka J, Ulys A, et al.
Int J Mol Sci
. 2021 Jul;
22(11).
PMID: 34198725
The molecular diversity of prostate cancer (PCa) has been demonstrated by recent genome-wide studies, proposing a significant number of different molecular markers. However, only a few of them have been...